Vical herpes

Oct 8, 2014 Vical has additional issued patents covering the composition and use of its Vaxfectin adjuvant. The six recently issued HSV-2 U.S. patents are Oct 3, 2014 After decades of stagnancy in the herpes therapeutics space, a real San Diego39s Vical are speeding ahead in developing a herpes vaccine

Feb 5, 2013 Vical Incorporated announces results of herpes vaccine trial testing its Vaxfectin-formulated plasmid DNA herpes vaccine on guinea pigs

An experimental HSV vaccine was not effective in preventing genital HSV-2 Vical Incorporated is a biopharmaceutical research company based in San Diego , Dec 17, 2013 The initiation of this trial represents another milestone for Vical Our trial is designed to demonstrate reductions in the rate of HSV-2 that is HSV-2 is a herpes virus that is the leading cause of genital herpes worldwide for HSV-2 or genital herpes Vical is developing a therapeutic HSV-2 vaccine

Vical - Vical Granted Six U.S. Patents for HSV-2 Vaccines

Sep 12, 2013 Vical39s HSV-2 DNA vaccine program, as seen below, involves collaboration with Lawrence Corey39s group at the Fred Hutchinson Research Vical HSV Clinical Trial. Healthy HSV-2 Positive Men and Women Needed for Herpes Study. People for Flyer Healthy men and women aged 19-50 who have

Dec 19, 2014 Some advancement on the herpes vaccine front: San Diego biotech Vical recently kicked off a Phase 12 trial of its Vaxfectin genital herpes Dec 20, 2013 Sponsor: Vical. Information provided by (Responsible Party): Vical MedlinePlus related topics: Genital Herpes Herpes Simplex